1 – 9 of 9
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Clinical, economic, and health-related quality of life burden associated with von Willebrand disease in adults and children : Systematic and targeted literature reviews
(
- Contribution to journal › Scientific review
-
Mark
Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B
(
- Contribution to journal › Article
- 2022
-
Mark
Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors
(
- Contribution to journal › Article
-
Mark
Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERS-IPS study
(
- Contribution to journal › Article
- 2020
-
Mark
Bleeding symptoms in patients diagnosed as type 3 von Willebrand disease : Results from 3WINTERS-IPS, an international and collaborative cross-sectional study
(
- Contribution to journal › Article
- 2013
-
Mark
Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A
(
- Contribution to journal › Article
- 2010
-
Mark
The impact of bleeding history, von Willebrand factor and PFA-100 (R) on the diagnosis of type 1 von Willebrand disease: results from the European study MCMDM-1VWD
(
- Contribution to journal › Article
- 2008
-
Mark
Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD
(
- Contribution to journal › Article
- 2007
-
Mark
Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD)
(
- Contribution to journal › Article